Q Is Monocyclic Patents (Class 514/604)
-
Patent number: 8829052Abstract: This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.Type: GrantFiled: September 23, 2011Date of Patent: September 9, 2014Assignee: Ardea Biosciences, Inc.Inventors: Andreas Maderna, Jean-Michel Vernier, Dinesh Barawkar, Varaprasad Chamakura, Hassan El Abdellaoul, Zhi Hong
-
Publication number: 20140243362Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR? wherein R1 to R7 are as defined in claim 35.Type: ApplicationFiled: September 25, 2012Publication date: August 28, 2014Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le
-
Publication number: 20140243374Abstract: This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of ?-secretase.Type: ApplicationFiled: October 4, 2012Publication date: August 28, 2014Inventors: Corinne E. Augelli-Szafran, Dai Lu, HanXun Wei, Jing Zhang, Michael S. Wolfe, Dennis J. Selkoe, Cuiman Cai
-
Publication number: 20140235636Abstract: The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.Type: ApplicationFiled: April 25, 2014Publication date: August 21, 2014Applicants: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins UniversityInventors: John P. Toscano, Art Sutton, Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
-
Patent number: 8809584Abstract: Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to N-substituted-N-phenylethylsulfonamides useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.Type: GrantFiled: December 21, 2011Date of Patent: August 19, 2014Assignee: Institut Univ. de Ciencia i Tecnologia, S.A.Inventors: Josep Castells Boliart, David Enrique Miguel Centeno, Marta Pascual Gilabert
-
Publication number: 20140221481Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: ApplicationFiled: April 10, 2014Publication date: August 7, 2014Applicant: Allergan, Inc.Inventors: HAIQING YUAN, RICHARD L. BEARD, XIAOXIA LIU, JOHN E. DONELLO, VEENA VISWANATH, MICHAEL E. GARST
-
Publication number: 20140213578Abstract: Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne.Type: ApplicationFiled: August 16, 2012Publication date: July 31, 2014Applicant: MT. SINAI SCHOOL OF MEDICINEInventors: Michael Ohlmeyer, Goutham Narla, Neil Dhawan, David Kastrinsky
-
Patent number: 8791161Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: GrantFiled: February 20, 2013Date of Patent: July 29, 2014Assignee: Allergan, Inc.Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, John E. Donello, Xiaoxia Liu, Veena Viswanath
-
Publication number: 20140206769Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.Type: ApplicationFiled: January 17, 2014Publication date: July 24, 2014Applicant: CARDIOXYL PHARMACEUTICALS, INC.Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
-
Publication number: 20140200239Abstract: The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase-1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.Type: ApplicationFiled: August 3, 2012Publication date: July 17, 2014Applicant: National Taiwan UniversityInventors: Chung-Wai Shiau, Kuen-Feng Chen
-
Patent number: 8779001Abstract: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.Type: GrantFiled: June 3, 2009Date of Patent: July 15, 2014Assignees: The United States of America National Institute of Health (NIH), The United States of America Dept. of Health and Human Services (DHHS)Inventors: David J. Tweardy, Xuejun Xu, Moses M. Kasembeli
-
Patent number: 8772541Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.Type: GrantFiled: December 14, 2012Date of Patent: July 8, 2014Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Xiang-qun Xie, Peng Yang, Rentian Feng
-
Publication number: 20140186295Abstract: Described herein are methods for the treatment of cancer (e.g. melanoma, lung cancer, or other cancers). The methods involve administrating to a subject in need thereof an agonist of the IL-9 receptor (e.g. IL-9), e.g. an agent that binds and activates the IL-9 receptor, or an agent that increases IL-9 expression in the subject (e.g. administration of TH9 cells that express IL-9, or administration of an inhibitor of ROR).Type: ApplicationFiled: March 22, 2012Publication date: July 3, 2014Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Thomas S. Kupper, Rahul Purwar
-
Patent number: 8759399Abstract: Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. This disclosure deals with the use of halo active aromatic sulfonamide organic compounds as odor control and/or biocidal agents in a cleaning solution for use with bovines and other dairy animals.Type: GrantFiled: August 17, 2011Date of Patent: June 24, 2014Inventors: David J. Schneider, Charles A. Schneider
-
Publication number: 20140161769Abstract: The present invention features a method of treating or reducing the likelihood of an inflammatory autoimmune disorder (e.g., systemic lupus erythematosus (SLE)) or a kidney disorder (e.g., glomerulonephritis) in a subject by administering an inhibitor of calcium/calmodulin-dependent protein kinase type IV (CaMKIV). The invention additionally features methods of diagnosing a subject with SLE or a kidney disorder by determining the level or biological activity of a CaMKIV nucleic acid or polypeptide in a sample from a subject. Also included in the invention are methods for identifying compounds that inhibit CaMKIV for the treatment of an inflammatory autoimmune disorder (e.g., SLE) or a kidney disorder (e.g., glomerulonephritis).Type: ApplicationFiled: July 8, 2013Publication date: June 12, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: George C. Tsokos, Yuang-Taung Juang, Chun-Shin Hahn
-
Publication number: 20140155477Abstract: Provided herein are substituted biaryl sulfonamide compounds, pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate initiation of protein translation. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.Type: ApplicationFiled: November 27, 2013Publication date: June 5, 2014Applicant: NOVOMEDIX, LLCInventors: Leah M. Fung, Kyle W.H. Chan, Cathy A. Swindlehurst, Robert W. Sullivan
-
Patent number: 8722742Abstract: Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.Type: GrantFiled: February 27, 2009Date of Patent: May 13, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Yuliet Mazola Reyes, Glay Chinea Santiago, Osmany Guirola Cruz, Roberto Vera Alvarez, Vivian Huerta Galindo, Noralvis Fleitas Salazar, Alexis Musacchio Lasa
-
Patent number: 8716285Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to processes for making said compounds and uses of said compounds, in particular their use as medicaments, more particularly their use as medicaments in the treatment of cancer.Type: GrantFiled: September 7, 2011Date of Patent: May 6, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Lei Guo, Guozhi Tang, Zhanguo Wang, Jason Christopher Wong, Weixing Zhang
-
Publication number: 20140113884Abstract: Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of making and using the compounds and compositions are further described.Type: ApplicationFiled: April 4, 2012Publication date: April 24, 2014Inventors: John David Imig, William B. Campell, John Russell Falck
-
Patent number: 8703749Abstract: A method of treating Friedreich's Ataxia with compounds of formula I including pharmaceutically acceptable salts, tautomers or stereoisomers of compounds of formula Lp.Type: GrantFiled: December 7, 2010Date of Patent: April 22, 2014Inventors: Roberto Testi, Ottaviano Incani
-
Publication number: 20140107160Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: October 9, 2013Publication date: April 17, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Geraldine C.B. Harriman, Zhan Shi, B. Shaowu Chen
-
Publication number: 20140087005Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.Type: ApplicationFiled: October 8, 2013Publication date: March 27, 2014Applicants: Fox Chase Cancer Center, The Trustees of the University of PennsylvaniaInventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy
-
Patent number: 8674132Abstract: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.Type: GrantFiled: June 22, 2012Date of Patent: March 18, 2014Assignees: The Johns Hopkins University, Cardioxyl Pharmaceuticals, Inc.Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
-
Publication number: 20140066388Abstract: Disclosed are compositions and methods for treating or preventing diseases or disorders associated with mitochondrial CaMKII activity.Type: ApplicationFiled: September 4, 2013Publication date: March 6, 2014Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Mark E. Anderson, Mei-ling A. Joiner, Aliasger K. Salem, Amaraporn Wongrakpanich, Frederick E. Domann, Duane D. Hall, Olha M. Koval, Douglas R. Spitz
-
Patent number: 8642506Abstract: The invention provides a plant disease control composition including active ingredients of (RS)-N-[2-(1,3-dimethylbutyl)thiophene-3-yl]-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide (common name: penthiopyrad) and at least one fungicidal compound other than penthiopyrad, and a plant disease prevention method wherein such a compound is applied to plant seeds or soil. According to the invention, a composition and a prevention method are provided which demonstrate a prevention effect against plural types of disease pathogenic microbes, and also demonstrate a preventing effect to currently emerging resistant pathogenic microbes, when applied to plant seed or soil.Type: GrantFiled: November 21, 2007Date of Patent: February 4, 2014Assignee: Mitsui Chemicals, Inc.Inventors: Seiya Sakurai, Junro Kishi, Hideo Kawashima
-
Publication number: 20140024608Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: ApplicationFiled: March 14, 2013Publication date: January 23, 2014Applicant: METHYLGENE INC.Inventors: Robert Deziel, Alain Ajamian
-
Patent number: 8629274Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.Type: GrantFiled: December 21, 2012Date of Patent: January 14, 2014Assignee: Novira Therapeutics, Inc.Inventors: George D. Hartman, Osvaldo A. Flores
-
Publication number: 20140005271Abstract: Provided herein are a composition for preventing or treating inflammatory diseases or infectious diseases which contains m-3M3FBS or a pharmaceutically available salt thereof as an active ingredient, and health supplements for improving or preventing inflammatory diseases or infectious diseases which contain m-3M3FBS. Since m-3M3FBS has a microbicidal effect, inhibition of apoptosis, and inhibition of LPS-involved signal transduction which enables to effectively treat or prevent inflammatory diseases or infectious diseases, so that it may be effectively used as medicine or health supplements for treating or preventing inflammatory diseases or infectious diseases.Type: ApplicationFiled: March 14, 2012Publication date: January 2, 2014Inventors: Yoe Sik Bae, Sang Doo Kim
-
Publication number: 20140005240Abstract: This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.Type: ApplicationFiled: July 18, 2013Publication date: January 2, 2014Inventors: Alan D. Snow, Qubai Hu, Thomas Lake, Judy Cam
-
Publication number: 20130331456Abstract: The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell.Type: ApplicationFiled: September 13, 2011Publication date: December 12, 2013Inventors: Arnab Basu, Debra M. Mills, John D. Williams, Bing Li, Norton P. Peet, Terry L. Bowlin
-
Publication number: 20130310384Abstract: This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of ?-secretase.Type: ApplicationFiled: October 4, 2011Publication date: November 21, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Corinne E. Augelli-Szafran, Dai Lu, Hanxun Wei, Jing Zhang, Michael S. Wolfe, Dennis J. Selkoe
-
Patent number: 8569377Abstract: The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.Type: GrantFiled: December 9, 2010Date of Patent: October 29, 2013Assignees: The United States of America as Represented by the Department of Veteran Affairs, University of Maryland, BaltimoreInventor: J. Marc Simard
-
Patent number: 8557812Abstract: The invention relates to small molecules which function as inhibitors of anti-apoptotic Bcl-2 family member proteins (e.g., Bcl-2 and Bcl-xL). The invention also relates to the use of these compounds for inducing apoptotic cell death and sensitizing cells to the induction of apoptotic cell death.Type: GrantFiled: August 22, 2005Date of Patent: October 15, 2013Assignee: The Regents of the University of MichiganInventors: Shaomeng Wang, Guoping Wang, Guozhi Tang, Renxiao Wang, Zaneta Nikolovska-Coleska, Dajun Yang, Liang Xu
-
Patent number: 8552050Abstract: The invention described herein features methods, compositions, and kits for the use of activators of PKM2 for the treatment, prevention, or amelioration of diseases related to PKM2 function, including, e.g., cancer, diabetes, atherosclerosis, restenosis, obesity, autoimmune disorders, and proliferative disorders.Type: GrantFiled: August 18, 2008Date of Patent: October 8, 2013Assignee: Beth Israel Deaconess Medical CenterInventors: Lewis C. Cantley, Matthew G. Vander Heiden, Heather R. Christofk
-
Publication number: 20130261178Abstract: A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein Z1 is C1-C4 linear or branched alkyl or alkenyl; R4 is selected from unsubstituted and substituted C3-C3 cycloalkyl, C1-C8 linear or branched alkyl, C2-5 alkenyl, C6-C10 heteroaryl or aryl, or C3-C8 heterocyclyl which may be part unsaturated, and combinations thereof; Z is linear C2-3 alkylene; X1 is selected from NH and O; X2 is selected from unsaturated C and unsaturated S; and X3 is selected from NH and CH2; or one of X1 and X3 is a single bond; or X1 is O and X2 and X3 together are a single bond; and R7 is selected from oxo, F, Cl, Br, CN, NH2, NR92, NO2, CF3, OR9, COR9, OCOR9, COOR9, NR9COR9, CONR92SO2NR92, NR9SO2R9; and R8 is selected from C1-5 alkyl, C1-5 alkoxyl, C2-5 alkenyl or alkynyl, C6-10 aryl and C3-8 cycloalkyl and combinations thereof, which may be unsubstituted or further substituted by one or more F, Cl, Br, CN, NH2, NR32, NO2, CF3;Type: ApplicationFiled: July 5, 2010Publication date: October 3, 2013Inventors: Shailesh Mistry, Etienne Daras, Christophe Fromont, Gopal Jadhav, Peter Martin Fischer, Barrie Kellam, Stephen John Hill, Jillian Glenda Baker
-
Publication number: 20130252984Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: ApplicationFiled: March 12, 2013Publication date: September 26, 2013Applicant: ALLERGAN, INC.Inventors: Haiqing YUAN, Richard L. BEARD, Xiaoxia LIU, John E. DONELLO, Veena VISWANATH, Michael E. GARST
-
Publication number: 20130245018Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicant: PIMCO 2664 LIMITEDInventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
-
Publication number: 20130237552Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: ApplicationFiled: April 29, 2013Publication date: September 12, 2013Applicant: ALLERGAN, INC.Inventors: HAIQING YUAN, RICHARD L. BEARD, MICHAEL E. GARST, JOHN E. DONELLO, XIAOXIA LIU, VEENA VISWANATH
-
Patent number: 8530520Abstract: The present invention is directed to carboxylic acid-containing pharmaceutical compounds where the carboxylic acid moieties have been substituted with cycloalkyl-dione derivatives, as well as tautomers and pharmaceutically acceptable salt forms thereof. These bioisosteric replacements improve the compound's ability to effectively cross the blood brain barrier and result in improved pharmacokinetic, toxicological, and/or safety profiles.Type: GrantFiled: June 6, 2012Date of Patent: September 10, 2013Assignee: The Trustees Of The University Of PennsylvaniaInventors: Onur Atasoylu, Carlo Ballatore, Kurt R. Brunden, Longchuan Huang, Donna M. Huryn, Michael James, Virginia M. Y. Lee, Francesco Piscitelli, Amos B. Smith, III, James Soper, John Q. Trojanowski
-
Publication number: 20130231332Abstract: The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses.Type: ApplicationFiled: September 1, 2011Publication date: September 5, 2013Inventors: James Cunningham, Kyungae Lee, Tao Ren, Kartik Chandran
-
Patent number: 8524778Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl sulfonamides and related compounds (collectively referred to herein as ‘BPSAAA compounds’), as described herein, and including, for example, biphenyl-4-sulfonic acid (hydroxyalkyl-phenyl)-amides and related compounds.Type: GrantFiled: March 20, 2008Date of Patent: September 3, 2013Assignee: PIMCO 2664 LimitedInventors: Iain Robert Greig, Robert Jurgen Van't Hof, Stuart Hamilton Ralston
-
Publication number: 20130217685Abstract: The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.Type: ApplicationFiled: January 8, 2013Publication date: August 22, 2013Applicant: UNIVERSITY OF MASSACHUSETTSInventor: University of Massachusetts
-
Publication number: 20130190356Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, A, B, C, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: ApplicationFiled: December 18, 2012Publication date: July 25, 2013Applicant: GENENTECH, INC.Inventor: Genetech, Inc.
-
Publication number: 20130190370Abstract: The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.Type: ApplicationFiled: July 27, 2011Publication date: July 25, 2013Applicant: The Trustees of the University of PennsylvaniaInventors: John Q. Trojanowski, Virginia M.Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huryn, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli
-
Publication number: 20130190288Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: ApplicationFiled: December 18, 2012Publication date: July 25, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Publication number: 20130190338Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: ApplicationFiled: March 11, 2013Publication date: July 25, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130184222Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.Type: ApplicationFiled: July 15, 2011Publication date: July 18, 2013Applicant: AGIOS PHARMACEUTICALS, INCInventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey Saunders, Jeremy Travins, Shunqi Yan
-
Publication number: 20130178533Abstract: The present invention relates to a composition for diagnosing, treating, and preventing liver disease, more particularly a composition for diagnosing liver disease comprising a material for measuring the grade of TM4SF5 (transmembrane 4 L six family member 5 or four-transmembrane L6 superfamily member 5) protein, a kit for diagnosing liver disease comprising the said composition, a method for providing information necessary for diagnosing liver disease composed of the following steps; measuring the level of TM4SF5 protein and the expressions and phosphorylations of TM4SF5 expression related signaling proteins; and comparing the measured levels with those of the normal control, a method for screening a material for treating liver disease, and a composition for treating or preventing liver disease comprising a material inhibiting TM4SF5 protein expression or the expressions and phosphorylations of TM4SF5 expression related signaling proteins.Type: ApplicationFiled: July 22, 2011Publication date: July 11, 2013Applicant: SNU R&DB FOUNDATIONInventors: Jung Weon Lee, Ki Hun Park, Min Kyung Kang
-
Publication number: 20130172388Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.Type: ApplicationFiled: December 14, 2012Publication date: July 4, 2013Applicant: University of Pittsburgh -- Of the Commonwealth System of Higher EducationInventor: University of Pittsburgh -- Of the Commonwealth System of Higher Education
-
Patent number: 8476306Abstract: The invention relates to novel inhibitors of urokinase and to their preparation and use for the therapy, prophylaxis and diagnosis of a tumor, in particular for reducing the formation of tumor metastases.Type: GrantFiled: November 22, 2010Date of Patent: July 2, 2013Assignee: The Medicines Company (Leipzig) GmbHInventors: Joerg Stuerzebecher, Torsten Steinmetzer, Andrea Schweinitz